Sarecycline Seysara denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sarecycline seysara are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sarecycline (Seysara) as Non-Formulary

Blue Cross Blue Shield's non-formulary denial means sarecycline is not included on your specific plan's drug list (formulary) or is placed on a tier that requires special approval before coverage is extended. Formularies differ by plan and year, so a drug covered under one BCBS plan may not be covered under another. A non-formulary denial does not mean the drug is clinically inappropriate — it means the plan has not placed it in a routinely covered category.

### Why This Denial Is Appealable

BCBS and other insurers are required to have a formulary exception process. If you or your prescriber can demonstrate that all covered alternatives are clinically unsuitable for your case — due to documented failures, intolerances, or clinical characteristics that make an alternative inappropriate — BCBS must consider approving a formulary exception. The ACA also requires plans to cover drugs in protected classes, and state insurance regulations may provide additional protections.

### Federal Appeal Framework

• Formulary exception / internal appeal: You can file a formulary exception request simultaneously with or as part of the internal appeal. Under ERISA §503 and ACA §2719, you are entitled to a full review.
• External review: If your formulary exception and internal appeal are denied, escalate to independent external review under ACA §2719, typically within about four months of the final denial.
• Expedited option: If your acne condition is causing urgent clinical harm (for example, severe scarring risk documented by your prescriber), request expedited review.

### Concrete Appeal Steps

1. Confirm your plan's current formulary by logging into your BCBS member portal or calling the number on your insurance card. 2. Identify which drugs BCBS has placed on covered tiers that treat the same condition, and request that your prescriber document why each covered alternative is not appropriate for you. 3. Obtain BCBS's formulary exception request form and submit it with supporting clinical documentation. 4. If the formulary exception is denied, file a formal internal appeal, then external review if needed. 5. Ask your prescriber to contact BCBS's peer-to-peer review line if available; a direct clinical conversation sometimes resolves non-formulary denials quickly.

### Documentation to Gather

• Diagnosis confirmation: Dermatology chart notes confirming acne vulgaris diagnosis and severity.
• Prior-treatment history with covered alternatives: Dates, duration, and documented outcomes or adverse effects for each formulary-tier antibiotic already tried.
• Clinical rationale for covered-alternative failure: Prescriber statement explaining, for each available formulary alternative, why it is not clinically appropriate for this patient.
• Prescriber medical-necessity letter: A letter directly requesting the formulary exception and summarizing the clinical case.
• Criteria mapping: Check BCBS's formulary exception policy for its required criteria; document the chart fact answering each requirement.

### Key Reminder

Formulary exception approvals are time-limited. If approved, confirm the duration and set a calendar reminder to reapply before it lapses. Each renewal requires the same documentation rigor as the original exception.